Skip to main content
SpringerLink
Log in

Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Recent researches suggest that imbalance in apoptotic process may lead to susceptibility to systemic lupus erythematosus (SLE). Production of pro-inflammatory cytokines, such as IL-18, has important role in autoimmune process in lupus. There are cumulative data on the pro-apoptotic role of IL-18, in the Fas-mediated apoptosis. Soluble Fas (Apo/1-CD95) is a marker of apoptosis that appears to increase in serum of SLE patients. Previous studies demonstrated increasing serum concentrations of soluble Fas (sFas) and IL-18 in SLE. To assess the correlation between serum concentrations of sFas and IL-18 in SLE patients, 114 SLE patients were selected randomly at the different stages of disease activity according to SLEDAI2K. IL-18 and sFas serum concentrations were compared in patients and fifty randomly selected healthy volunteers. The correlations of IL-18 and sFas serum concentrations with SLEDAI2K and with each other were evaluated in patients. There were a significant difference between serum concentrations of sFas and IL-18 in the case and control groups (P = 0.001). There was a significant correlation between serum concentrations of sFAS and IL-18 in SLE patients (P < 0.0001, r = 0.411). The elevations of IL-18 and sFas(Apo/1-CD95) serum concentrations in SLE patients are significantly correlated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J (2008) Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 17:371–375

    Article  PubMed  CAS  Google Scholar 

  2. Sahin M, Aydıntug O, Tunc SE, Tutkak H, Nazıroğlu M (2007) Serum soluble Fas levels in patients with autoimmune rheumatic diseases. Clin Biochem 40:6–10

    Article  PubMed  CAS  Google Scholar 

  3. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40:1126–1129

    Article  PubMed  CAS  Google Scholar 

  4. Hao JH, Ye DQ, Zhang GQ, Liu HH, Dai H, Huang F, Pan FM, Su H, Dong MX, Chen H, Wang Q, Zhang XJ (2006) Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese. Arch Dermatol Res 297(7):329–332

    Article  PubMed  CAS  Google Scholar 

  5. Alecu M, Coman G, Alecu S (2000–2001) Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus. Rom J Intern Med 38–39:83–88

    Google Scholar 

  6. Courteny PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL (1999) Lymphocyte apoptosis in systemic lupus erythematosus, relationship with Fas expression, serum soluble FAS and diease activity. Lupus 8:508–513

    Article  Google Scholar 

  7. Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F (2003) Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus 12:8–14

    Article  PubMed  CAS  Google Scholar 

  8. Carroll HP, Paunovic V, Gadina M (2008) Crossed signals: the role of interlukin-15 and -18 in autoimmunity. Rheumatology 47:1269–1277

    Article  PubMed  CAS  Google Scholar 

  9. Boraschi D, Dinarello CA (2006) IL-18 in autoimmunity: review. Eur Cytokine Netw 17(4):224–252

    PubMed  CAS  Google Scholar 

  10. Calvani N, Richards HB, Tucci M, Pannarale G, Silvester F (2004) Upregulation of IL-18 and predominance of Th1 immune response is a hallmark of lupus nephritis. Clin Xp Immunol 138:171–178

    Article  CAS  Google Scholar 

  11. Park MC, Park YB, Lee SK (2004) Elevated interlukin- 18 levels correlated with disease activity in systemic lupus erythematosus. Clin Rheumatol 23:225–229

    Article  PubMed  Google Scholar 

  12. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M (1997) Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 17:3253–3258

    PubMed  CAS  Google Scholar 

  13. Kitaura H, Tatamiya M, Nagata N, Fujimura Y, Eguchi T, Yoshida N, Nakayama K (2006) IL-18 induces apoptosis of adherent bone marrow cells in TNF- α mediated osteoclast formation in synergy with IL-12. Immunol Lett 107:22–31

    Article  PubMed  CAS  Google Scholar 

  14. Reddy P (2004) Interleukin-18: recent advances. Curr Opin Hematol 11:405–410

    Article  PubMed  CAS  Google Scholar 

  15. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H (1996) Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 173:230–235

    Article  PubMed  CAS  Google Scholar 

  16. Chen DY, Hsieh TY, Hsieh CW, Lin FJ, Lan JN (2007) Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset still’s disease. Arthritis Rheum (Arthritis Care Res) 57:1530–1538

    Article  Google Scholar 

  17. Marín-Serrano E, Rodríguez-Ramos C, Díaz F, Martín-Herrera L, Girón-González JA (2006) Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J Viral Hepat. 13:230–234

    Article  PubMed  Google Scholar 

  18. Nakae H, Zheng YJ, Wada H, Tajimi K, Endo S (2003) Involvement of IL-18 and soluble fas in patients with postoperative hepatic failure. Eur Surg Res 35:61–66

    Article  PubMed  CAS  Google Scholar 

  19. El-Masry S, Lotfy M, Nasif WA, El-Kady IM, Al-Badrawy M (2007) Elevated serum level of interleukin (IL)-18, interferon (IFN)-gamma and soluble Fas in patients with pulmonary complications in tuberculosis. Acta Microbiol Immunol Hung 54:65–77

    Article  PubMed  CAS  Google Scholar 

  20. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725

    Article  PubMed  CAS  Google Scholar 

  21. Dalboni MA, Sardenberg C, Andreoli MC, Watanabe R, Canziani ME, Santos BF, Liangos O, Jaber BL, Draibe S, Cendoroglo M (2003) Soluble FAS a novel marker of inflammation in uremia. Artif Organs 27:678–691

    Article  Google Scholar 

  22. Sahebari M, hatef, Rezaiyeyazdi Z, Abbasi M, Abbasi B, Mahmoudi M (2010) Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in khorasan. Iran. Arch Iran Med 13:135–142

    CAS  Google Scholar 

  23. Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, Beri R, Dolcino M, Martinelli N, Corrocher R, Lunardi C (2009) Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. Int Immunol. doi:10.1093/intimm/dxn142

    PubMed  Google Scholar 

  24. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H (1999) Differential anti tumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 163:583–589

    PubMed  CAS  Google Scholar 

  25. Satoko I, Nobuhiro S, Yoshihiro I, Shigeatsu E (2005) A study of interleukin 18 and sFas in septic multiple organ dysfunction syndrome. J Iwate Med A 5:497–503

    Google Scholar 

  26. Mariño E, Cardier JE (2003) Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-a and Fas (CD95). Cytokine 22:142–148

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This research was financially supported by a grant provided by the Chancellor for Research of Mashhad University of Medical Science, Mashhad, Iran. We are grateful to all patients & healthy volunteers for their kind participation.

Author information

Authors and Affiliations

  1. Rheumatic Diseases Research Center, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Maryam Sahebari, Zahra Rezaieyazdi, Mohammadreza Hatef & Saaid Akhlaghi

  2. Tabriz University of Medical Sciences, Tabriz, Iran

    Mohammadreza J. Nakhjavani

  3. Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Mahmoud Mahmoudi

Authors
  1. Maryam Sahebari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zahra Rezaieyazdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammadreza J. Nakhjavani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammadreza Hatef
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mahmoud Mahmoudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Saaid Akhlaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zahra Rezaieyazdi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sahebari, M., Rezaieyazdi, Z., Nakhjavani, M.J. et al. Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus. Rheumatol Int 32, 601–606 (2012). https://doi.org/10.1007/s00296-010-1633-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-010-1633-9

Keywords

Search

Navigation